Lone Peak Global Investors LLC Acquires 9,062 Shares of Becton, Dickinson and Company $BDX

Key Points

• Lone Peak Global Investors increased its Becton, Dickinson and Company stake by 6.2% in the second quarter, purchasing 9,062 additional shares and bringing its holdings to 156,130 shares valued at approximately $23.6 million.
• BDX reported quarterly earnings of $3.23 per share and revenue of $4.98 billion, surpassing analyst expectations, while revenue rose 5.4% year over year. The company issued fiscal 2026 EPS guidance of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05 per share, equivalent to an annualized $4.20 payout and a 2.2% yield. Analysts maintain a consensus “Hold” rating with an average price target of $187.67.

Lone Peak Global Investors LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,130 shares of the medical instruments supplier's stock after purchasing an additional 9,062 shares during the period. Becton, Dickinson and Company comprises 3.3% of Lone Peak Global Investors LLC's holdings, making the stock its 12th largest position. Lone Peak Global Investors LLC owned approximately 0.06% of Becton, Dickinson and Company worth $23,627,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BDX. Auto Owners Insurance Co increased its holdings in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $3,721,533,000. State Street Corp lifted its stake in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock valued at $2,714,871,000 after purchasing an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock valued at $1,331,165,000 after buying an additional 53,884 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.5%

Shares of NYSE:BDX opened at $187.23 on Wednesday. The firm has a fifty day moving average price of $167.95 and a two-hundred day moving average price of $160.37. The company has a market cap of $51.59 billion, a price-to-earnings ratio of 56.39, a PEG ratio of 13.26 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 9,105 shares of company stock worth $1,590,208 over the last three months. Company insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BDX shares. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Bank of America increased their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source